Aligos Therapeutics Files 8-K with Key Agreements and Disclosures
Ticker: ALGS · Form: 8-K · Filed: Feb 12, 2025 · CIK: 1799448
| Field | Detail |
|---|---|
| Company | Aligos Therapeutics, Inc. (ALGS) |
| Form Type | 8-K |
| Filed Date | Feb 12, 2025 |
| Risk Level | medium |
| Pages | 7 |
| Reading Time | 8 min |
| Key Dollar Amounts | $0.0001, $26.0825, $26.0824, $26, $0 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, disclosure
TL;DR
Aligos Therapeutics filed an 8-K on Feb 11, 2025, covering material agreements, equity sales, and disclosures.
AI Summary
On February 11, 2025, Aligos Therapeutics, Inc. filed an 8-K report detailing several key events. The company entered into a material definitive agreement, engaged in unregistered sales of equity securities, and made a Regulation FD disclosure. The filing also included financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate actions by Aligos Therapeutics, including potential new financing or partnerships and regulatory disclosures that could impact investor understanding of the company's financial and operational status.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can carry inherent risks and require careful investor scrutiny.
Key Numbers
- 001-39617 — SEC File Number (Identifies the company's filing with the SEC.)
Key Players & Entities
- Aligos Therapeutics, Inc. (company) — Registrant
- February 11, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-39617 (identifier) — SEC File Number
- One Corporate Dr., 2nd Floor South San Francisco, CA 94080 (address) — Principal executive offices
FAQ
What type of material definitive agreement did Aligos Therapeutics enter into?
The filing does not specify the exact nature of the material definitive agreement, only that one was entered into on or before February 11, 2025.
What was the purpose of the unregistered sales of equity securities?
The filing does not provide details on the purpose or terms of the unregistered sales of equity securities.
What information was disclosed under Regulation FD?
The filing indicates a Regulation FD disclosure was made, but the specific content of this disclosure is not detailed within the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 11, 2025.
What is Aligos Therapeutics, Inc.'s principal executive office address?
Aligos Therapeutics, Inc.'s principal executive office is located at One Corporate Dr., 2nd Floor, South San Francisco, CA 94080.
Filing Stats: 1,983 words · 8 min read · ~7 pages · Grade level 12.9 · Accepted 2025-02-12 08:52:21
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share ALGS The Nasdaq
- $26.0825 — hare and accompanying Common Warrant is $26.0825 and the combined price per Pre-Funded W
- $26.0824 — rant and accompanying Common Warrant is $26.0824. The closing of the Private Placement i
- $26 — rant has an exercise price per share of $26.02, became immediately exercisable on t
- $0 — s a nominal exercise price per share of $0.0001, became immediately exercisable on
- $105 m — the Private Placement are approximately $105 million, before deducting the placement a
Filing Documents
- d901857d8k.htm (8-K) — 41KB
- d901857dex41.htm (EX-4.1) — 73KB
- d901857dex42.htm (EX-4.2) — 83KB
- d901857dex101.htm (EX-10.1) — 254KB
- d901857dex102.htm (EX-10.2) — 126KB
- d901857dex103.htm (EX-10.3) — 74KB
- d901857dex104.htm (EX-10.4) — 20KB
- d901857dex991.htm (EX-99.1) — 10KB
- g901857dsp50.jpg (GRAPHIC) — 4KB
- 0001193125-25-024838.txt ( ) — 983KB
- algs-20250211.xsd (EX-101.SCH) — 3KB
- algs-20250211_lab.xml (EX-101.LAB) — 18KB
- algs-20250211_pre.xml (EX-101.PRE) — 11KB
- d901857d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 4.1 Form of Pre-Funded Warrant. 4.2 Form of Common Warrant. 10.1 Securities Purchase Agreement, dated February 11, 2025, by and among the Company and the Purchasers. 10.2 Form of Registration Rights Agreement. 10.3 Form of Lead Investor Registration Rights Agreement. 10.4 Form of Letter Agreement. 99.1 Press Release, dated February 12, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALIGOS THERAPEUTICS, INC. Date: February 12, 2025 By: /s/ Lesley Ann Calhoun Lesley Ann Calhoun Executive Vice President, Chief Operating Officer and Chief Financial Officer